People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NexImmune, Inc. | — | Biotechnology | Series B | $35.0M | $308.3M | 2011 |
| Noble Life Sciences, Inc. | — | Biotechnology | Pre-Seed | $235K | $13.0M | 2010 |
Alain Cappeluti at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alain Cappeluti on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth Carter | 2 | 6 |
| Robert Spiegel | 1 | 8 |
| James Barrett | 1 | 6 |
| Tony Yao | 1 | 3 |
| Janis Naeve | 1 | 3 |
| Timothy Bertram | 1 | 2 |
| Alan Roemer | 1 | 2 |
| Bing Yao | 1 | 1 |
| Slain Cappeluti | 1 | 1 |
| Scott Carmer | 1 | 1 |
| Paul D'Angio | 1 | 1 |
| Jonathan Schneck | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.